Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort

S. W. Lee, Seung Heon Lee, J. J. Yim

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: Interferon-gamma release assay (IGRA) results have been suggested as a surrogate marker of treatment response in latent tuberculosis infection (LTBI). However, data have not been consistent, and most previous studies focused on participants taking isoniazid prophylaxis. The aim of this study was to elucidate the changes in the IGRA results in patients who underwent chemoprophylaxis with isoniazid and rifampicin daily for 3 months. Methods: In a TB outbreak cohort, 26 asymptomatic close contacts with normal chest radiographs and positive QuantiFERON-TB Gold In-Tube assay (QFT-GIT) results were recruited. These patients were treated with isoniazid and rifampicin daily for 3 months. The QFT-GIT was repeated at 3 and 6 months following treatment initiation. Results: Compared with the initial QFT-GIT results (3.59 ± 3.39 IU/mL), the interferon-gamma (IFN-γ) levels had decreased significantly at 6 months (0.84 ± 1.14 IU/mL; P = 0.005), but not at 3 months (3.58 ± 3.64 IU/mL; P = 0.98). Reversions occurred in seven (26.9 %) patients at 3 months and in an additional two participants at 6 months; a total of nine participants (34.6 %) had reversions. Recent conversion was associated with reversion of the test results (odds ratio 26.3, 95 % confidence interval 3.04-226.6). Conclusion Chemoprophylaxis with isoniazid and rifam-picin generally decreased IFN-y levels among tuberculosis contacts. However, only a small portion of participants achieved reversion.

Original languageEnglish
Pages (from-to)431-435
Number of pages5
JournalInfection
Volume40
Issue number4
DOIs
Publication statusPublished - 2012 Aug 1
Externally publishedYes

Fingerprint

Interferon-gamma Release Tests
Isoniazid
Chemoprevention
Disease Outbreaks
Tuberculosis
Gold
Rifampin
Interferon-gamma
Latent Tuberculosis
Thorax
Biomarkers
Odds Ratio
Confidence Intervals
Therapeutics

Keywords

  • Interferon-γ release assay
  • Latent tuberculosis infection
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. / Lee, S. W.; Lee, Seung Heon; Yim, J. J.

In: Infection, Vol. 40, No. 4, 01.08.2012, p. 431-435.

Research output: Contribution to journalArticle

@article{96066b1432bb48aab9cd3f9acd798c34,
title = "Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort",
abstract = "Purpose: Interferon-gamma release assay (IGRA) results have been suggested as a surrogate marker of treatment response in latent tuberculosis infection (LTBI). However, data have not been consistent, and most previous studies focused on participants taking isoniazid prophylaxis. The aim of this study was to elucidate the changes in the IGRA results in patients who underwent chemoprophylaxis with isoniazid and rifampicin daily for 3 months. Methods: In a TB outbreak cohort, 26 asymptomatic close contacts with normal chest radiographs and positive QuantiFERON-TB Gold In-Tube assay (QFT-GIT) results were recruited. These patients were treated with isoniazid and rifampicin daily for 3 months. The QFT-GIT was repeated at 3 and 6 months following treatment initiation. Results: Compared with the initial QFT-GIT results (3.59 ± 3.39 IU/mL), the interferon-gamma (IFN-γ) levels had decreased significantly at 6 months (0.84 ± 1.14 IU/mL; P = 0.005), but not at 3 months (3.58 ± 3.64 IU/mL; P = 0.98). Reversions occurred in seven (26.9 {\%}) patients at 3 months and in an additional two participants at 6 months; a total of nine participants (34.6 {\%}) had reversions. Recent conversion was associated with reversion of the test results (odds ratio 26.3, 95 {\%} confidence interval 3.04-226.6). Conclusion Chemoprophylaxis with isoniazid and rifam-picin generally decreased IFN-y levels among tuberculosis contacts. However, only a small portion of participants achieved reversion.",
keywords = "Interferon-γ release assay, Latent tuberculosis infection, Tuberculosis",
author = "Lee, {S. W.} and Lee, {Seung Heon} and Yim, {J. J.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/s15010-012-0265-2",
language = "English",
volume = "40",
pages = "431--435",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel",
number = "4",

}

TY - JOUR

T1 - Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort

AU - Lee, S. W.

AU - Lee, Seung Heon

AU - Yim, J. J.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Purpose: Interferon-gamma release assay (IGRA) results have been suggested as a surrogate marker of treatment response in latent tuberculosis infection (LTBI). However, data have not been consistent, and most previous studies focused on participants taking isoniazid prophylaxis. The aim of this study was to elucidate the changes in the IGRA results in patients who underwent chemoprophylaxis with isoniazid and rifampicin daily for 3 months. Methods: In a TB outbreak cohort, 26 asymptomatic close contacts with normal chest radiographs and positive QuantiFERON-TB Gold In-Tube assay (QFT-GIT) results were recruited. These patients were treated with isoniazid and rifampicin daily for 3 months. The QFT-GIT was repeated at 3 and 6 months following treatment initiation. Results: Compared with the initial QFT-GIT results (3.59 ± 3.39 IU/mL), the interferon-gamma (IFN-γ) levels had decreased significantly at 6 months (0.84 ± 1.14 IU/mL; P = 0.005), but not at 3 months (3.58 ± 3.64 IU/mL; P = 0.98). Reversions occurred in seven (26.9 %) patients at 3 months and in an additional two participants at 6 months; a total of nine participants (34.6 %) had reversions. Recent conversion was associated with reversion of the test results (odds ratio 26.3, 95 % confidence interval 3.04-226.6). Conclusion Chemoprophylaxis with isoniazid and rifam-picin generally decreased IFN-y levels among tuberculosis contacts. However, only a small portion of participants achieved reversion.

AB - Purpose: Interferon-gamma release assay (IGRA) results have been suggested as a surrogate marker of treatment response in latent tuberculosis infection (LTBI). However, data have not been consistent, and most previous studies focused on participants taking isoniazid prophylaxis. The aim of this study was to elucidate the changes in the IGRA results in patients who underwent chemoprophylaxis with isoniazid and rifampicin daily for 3 months. Methods: In a TB outbreak cohort, 26 asymptomatic close contacts with normal chest radiographs and positive QuantiFERON-TB Gold In-Tube assay (QFT-GIT) results were recruited. These patients were treated with isoniazid and rifampicin daily for 3 months. The QFT-GIT was repeated at 3 and 6 months following treatment initiation. Results: Compared with the initial QFT-GIT results (3.59 ± 3.39 IU/mL), the interferon-gamma (IFN-γ) levels had decreased significantly at 6 months (0.84 ± 1.14 IU/mL; P = 0.005), but not at 3 months (3.58 ± 3.64 IU/mL; P = 0.98). Reversions occurred in seven (26.9 %) patients at 3 months and in an additional two participants at 6 months; a total of nine participants (34.6 %) had reversions. Recent conversion was associated with reversion of the test results (odds ratio 26.3, 95 % confidence interval 3.04-226.6). Conclusion Chemoprophylaxis with isoniazid and rifam-picin generally decreased IFN-y levels among tuberculosis contacts. However, only a small portion of participants achieved reversion.

KW - Interferon-γ release assay

KW - Latent tuberculosis infection

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84866731322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866731322&partnerID=8YFLogxK

U2 - 10.1007/s15010-012-0265-2

DO - 10.1007/s15010-012-0265-2

M3 - Article

C2 - 22585454

AN - SCOPUS:84866731322

VL - 40

SP - 431

EP - 435

JO - Infection

JF - Infection

SN - 0300-8126

IS - 4

ER -